What Accent Therapeutics’ AACR 2026 ATX-295 update reveals about the next wave of precision oncology targets

Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.

Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.